[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bmi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bmi":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,93,124,148,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":39,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100054125","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100054125",false,"NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.","FEMALE","18 Years",{"count":20,"type":21},115,"ESTIMATED","OBSERVATIONAL","We therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Chemotherapy","Radiotherapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[40,41,42],"Comparative","observational","retrospective","NOT_YET_RECRUITING","2026-07-07",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":21},"2026-07-10",{"date":51,"type":21},"2026-08-20",{"name":53,"class":54},"University Hospital, Grenoble","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100635720","empowering-faith-based-communities-to-provide-personalized-diabetes-self-management-education-and-support-dsmes-in-the-magic-city-100635720","NCT07556354","Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City","Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City: A Pilot Study","MCPILOTDSMES","Inclusion Criteria:\n\n* Have a prior diabetes (Type 1, Type 2, or Gestational) or prediabetes diagnosis\n* Are aged 18 or older\n* Live in Jefferson County, Alabama\n* Have never participated in a DSMES program\n\nExclusion Criteria:\n\n* Not a resident of Jefferson County, Alabama\n* Completed a DSMES program",true,"ALL",{"count":66,"type":21},30,"INTERVENTIONAL",[69],"NA","In this study, individuals living with diabetes in the Birmingham area will participate in a free, 3-month DSMES program hosted by MedsPLUS Consulting, a local independent pharmacy and wellness center, at a local faith-based organization. DSMES sessions meet twice a month and typically address topics including physical activity, nutrition, coping, and reducing risk and complications. Prior to beginning the program, participants will complete a questionnaire that assesses diabetes self-management behaviors (such as diet, physical activity, and medication adherence) and diabetes knowledge. Additionally, they will participate in a biometric screening where clinical data such as blood A1C, blood pressure, blood cholesterol, and BMI are collected. This data will also be collected again after the completion of the program. In this program, participants will be assigned a community health worker who will contact them outside of scheduled DSMES sessions to provide support. Participants will also be randomly assigned to one of two cohorts, the Traditional cohort and the Remote Patient Monitoring (RPM) cohort. The traditional cohort will use paper trackers to track blood pressure and blood sugar outside of DSMES sessions while the RPM cohort will utilize an RPM platform to track this data.",[72,73,74,27,75,76],"Blood Cholesterol","Blood Pressure Monitoring","Weight Change","Diabetes Education","Diabetes (DM)",[78,79,80,81],"dsmes","diabetes education","faith based intervention","remote patient monitoring","RECRUITING","2026-06-29",{"date":85,"type":47},"2026-07-01",{"date":87,"type":21},"2026-07",{"date":89,"type":21},"2026-10",{"name":91,"class":54},"University of Alabama at Birmingham",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":67,"phases":103,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":92},"100620863","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-mb-1-on-metabolic-health-in-overweight-and-obese-adults-100620863","NCT07363148","A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","Inclusion Criteria:\n\n1. Males \\& females aged 18-50 years, inclusive\n2. BMI of 25.0 to ≤ 34.9 kg\u002Fm²\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically-approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n4. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline as assessed by the QI\n5. Abdominal obesity: Waist circumference of \\> 94 cm (37 inches) in men and \\> 80 cm (31.5 inches) in women\n6. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits\n7. Agrees to maintain current lifestyle habits (diet, medications, supplements, and sleep) as much as possible throughout the study\n8. Provided voluntary, written, informed consent to participate in the study\n9. Healthy as determined by medical history as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of the investigational product or placebo ingredients\n3. Gastric bypass surgery or other surgeries to induce weight loss\n4. Metal implants or other physical characteristics\u002Flimitations that may affect DEXA scan results as assessed by the QI\n5. Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI\n6. Current or history of eating disorders as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n10. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n11. Type I or Type II diabetes\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Self reported confirmation of glaucoma\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n26. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n27. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n28. Individuals who are unable to give informed consent\n29. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","50 Years",{"count":102,"type":21},120,[69],"The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is:\n\nWhat is the difference in change in body weight from baseline at Day 84 between MB-1 and placebo?\n\nParticipants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.",[106,107,108,109,27],"Obese","Overweight Adults","Obese Adults","Body Weight Control",[111,112,113,114],"Arrae","MB-1","Obesity","Overweight","2026-06-26",{"date":117,"type":47},"2026-06-30",{"date":119,"type":21},"2026-08",{"date":121,"type":21},"2027-01",{"name":111,"class":123},"INDUSTRY",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":63,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":131,"targetDuration":4,"studyType":67,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":92},"100578992","effects-of-body-composition-on-vascular-health-in-females-with-a-healthy-body-weight-100578992","NCT06818500","Effects of Body Composition on Vascular Health in Females With a Healthy Body Weight","Resting Indicators of Vascular Health and Cardiovascular Reactivity in Females With \"Normal-Weight Obesity\"","Inclusion Criteria:\n\n* You are 18-50 years old\n* Your biological sex is female\n* BMI is in \"normal\" category (18.5-24.9 kg\u002Fm2) - this BMI requirement is due to our research aims\n* You are not pregnant or expecting to become pregnant\n* You are not postmenopausal\n* You have not been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)\n* You have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* You do not regularly take anti-inflammatory drugs (more than 2x week) or are able to temporarily suspend use of anti-inflammatory drugs.\n* You do not use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs\n* You do not have a pacemaker.\n* You do not have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* You are able to stay in the supine position in the dark for at least 10 minutes\n\nExclusion Criteria:\n\n* You are not 18-50 years old\n* Your biological sex is not female\n* Your BMI is not in the \"normal\" category (18.5-24.9 kg\u002Fm2) - this BMI requirement is due to our research aims\n* You are pregnant or expecting to become pregnant (females only)\n* You are postmenopausal\n* You have been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)\n* You have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* You regularly take anti-inflammatory drugs (more than 2x week) or are unable to temporarily suspend use of anti-inflammatory drugs.\n* You use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs\n* You have a pacemaker.\n* You do have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* You are unable to stay in the supine position in the dark for at least 10 minutes",{"count":66,"type":21},[69],"Most of the time, body weight is evaluated by looking at the ratio of your weight to your height. This measurement is called body mass index or BMI. However, BMI does not account for what your body is actually made up of (e.g., body fat versus muscle), which may be more important for determining cardiovascular disease risk. The investigators aim to understand vascular health in females with a \"healthy\" BMI with differing amounts of body fat and muscle mass. We will have participants come to the lab for two different study visits. At one visit, participants will eat a meal high in fat, and at the other visit, participants will undergo a stress task.",[135,27,136],"Normal-weight Obesity","Stress",[27,136,138],"Healthy BMI","2026-04-22",{"date":141,"type":47},"2026-04-24",{"date":143,"type":47},"2024-09-01",{"date":145,"type":21},"2027-05-31",{"name":147,"class":54},"Ball State University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":63,"sex":64,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":67,"phases":159,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":92},"100630932","evaluating-care-integration-between-pediatric-primary-care-providers-and-wic-nutritionists-100630932","NCT07494097","Evaluating Care Integration Between Pediatric Primary Care Providers and WIC Nutritionists","Evaluating Care Integration Between Pediatric Primary Care Providers and WIC Nutritionists for Early Obesity Prevention Among WIC Mothers and Children","WEE Baby","Inclusion Criteria:\n\n* People who are a) pregnant and \\>34 weeks' gestation or b) who have an infant \\\u003C2 months old\n* 18-40 years old\n* English and\u002For Spanish speaking and reading\n* Access to a smartphone or internet-connected device\n* Not planning to move out of Pennsylvania within 2 years\n* Not planning to change health care providers outside of Geisinger within 2 years\n* Custody of and lives with (or will live with) the child enrolled in the study\n* Child must have a Geisinger PCP and be a WIC participant or eligible for WIC at enrollment\n\nExclusion Criteria:\n\n* Mother is not interested (or willing) to enroll in WIC\n* Child has a genetic or developmental disorder (e.g., cleft palate) that impacts weight or feeding\n* Child has a terminal condition","40 Years",{"count":158,"type":21},380,[69],"This study looks at whether using secure digital systems to share information between pediatric health care providers (during regular well-child visits) and social care providers (during regular visits with WIC nutritionists) can help mothers receive consistent guidance on responsive parenting to support healthy child growth and development. Responsive parenting means learning how to respond to a baby's needs in ways that support healthy eating, sleep, activity, and emotion regulation habits. The main questions this study aims to answer are:\n\n1. Does using secure digital systems to share information between pediatric health care providers and social care providers help mothers receive consistent guidance on responsive parenting to support healthy growth from birth to 24 months?\n2. Does using secure digital systems to share information between pediatric health care providers and social care providers help mothers receive consistent guidance on responsive parenting, improve responsive parenting practices and child diet quality?\n\nThe investigators will compare the group that receives secure digital systems for sharing information on responsive parenting to a group that receives standard care (does not receive this) to see if secure digital systems for sharing information on responsive parenting work to support healthy child growth and development. The goal is to see if this approach can improve early health behaviors and reduce health disparities for families in rural, low-income communities.",[162,27,163,164,165],"Weight Gain Trajectory","Responsive Parenting","Diet Quality","Implementation",[167,163,168],"Child Weight","Health Information Technologies","2026-03-19",{"date":171,"type":47},"2026-03-27",{"date":119,"type":21},{"date":174,"type":21},"2029-12",{"name":176,"class":54},"Penn State University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":187,"studyType":22,"phases":4,"briefSummary":188,"conditions":189,"keywords":193,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":92},"100604004","prognostic-impacts-of-lipid-profile-and-bmi-in-adult-aml-100604004","NCT07143877","Prognostic Impacts of Lipid Profile and BMI in Adult AML","Prognostic Impacts of Lipid Profile and Body Mass Index in Adult Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy","AML\u002FBMI","Inclusion Criteria:\n\n* Adult patients (≥18yearsold) newly diagnosed with AML.\n* Patients eligible for intensive induction chemotherapy.\n* Patients who have given informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with secondary or relapsed AML.\n* Patients currently using lipid-lowering medications (e.g., statins).\n* Patients with known endocrine or metabolic disorders affecting BMI or lipid profile (e.g., uncontrolled diabetes, hypothyroidism, Cushing's syndrome).\n* Pregnant or lactating women.\n* Patients unwilling or unable to complete the study protocol.\n* Patients with M3 subtype of AML.",{"count":186,"type":21},200,"35 Days","The goal of this observational study is to evaluate the changes in lipid profile parameters (total cholesterol, triglycerides, HDL-C, and LDL-C) in adult AML patients before and after intensive induction chemotherapy. The main questions it aims to answer are:\n\n* Are there correlations between metabolic changes (in lipid profile and BMI) and treatment outcomes, including remission status and incidence of chemotherapy-related complications?\n* Can the baseline lipid profile and BMI serve as prognostic markers for response to induction chemotherapy.?\n\nParticipants will be observed before and after induction chemotherapy regarding their lipid profile, and BMI, observing any correlations between the different results with any complications, and with remission status.",[190,27,191,192],"AML (Acute Myeloid Leukemia)","Lipid Profile","Induction Chemotherapy",[194,27,195,196,197],"AML","Lipid profile","Adult","Induction chemotherapy","2025-08-23",{"date":200,"type":47},"2025-08-27",{"date":202,"type":21},"2025-11-15",{"date":204,"type":21},"2027-03-15",{"name":206,"class":54},"Assiut University"]